BETAGAN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETAGAN is an ophthalmic solution approved in 1989 for the treatment of glaucoma and ocular hypertension. As a small-molecule beta-blocker eye drop, it works by reducing intraocular pressure through adrenergic receptor antagonism. The product is now in its late lifecycle stage with loss of exclusivity approaching.
LOE Approaching
A mature ophthalmology product with moderate competitive pressure (30/100) facing near-term generic erosion; expect smaller commercial teams focused on managed care and patient retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BETAGAN offers exposure to mature market dynamics, managed care negotiation, and generic defense strategies in a stable therapeutic category. Career progression may involve transitioning to emerging programs or developing expertise in lifecycle management and market access.
Brand ManagerMedical Science Liaison
Worked on BETAGAN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.